Repligen
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug product...
Latest News
12 days ago · fool.com
Repligen: 3 Key Takeaways for Long-Term InvestorsRepligen delivered revenue of $209 million in the third quarter. BioLife is expected to contribute $24 million in fourth-quarter revenue.
13 days ago · globenewswire.com
Repligen Corporation to Present at Jefferies Global Healthcare ConferenceWALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion on November 18th at 2:00 p.m. GMT.
18 days ago · globenewswire.com
Repligen Announces $1 Billion Private Convertible Senior Notes TransactionWALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% Convertible Senior Notes due 2028 (the “2028 Notes”) and certain new investors, pursuant to which Repligen will issue $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 (the “New Notes”). Approximately $541.4 million principal amount of the New Notes will be issued in exchange for approximately $456.8 million principal amount of 2028 Notes (the “Exchange Transactions”) and approximately $458.6 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $226.37 per share of Repligen's common stock, which represents a conversion premium of approximately 20% over the closing price of Repligen's common stock on October 29, 2026, subject to customary anti-dilution adjustments. Following the closing of the Transactions, which is expected to occur on or about November 6, 2026, subject to customary closing conditions, approximately $143.2 million in aggregate principal amount of 2028 Notes will remain outstanding with terms unchanged.
20 days ago · seekingalpha.com
Repligen Corporation (RGEN) Q3 2026 Earnings Call TranscriptRepligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
21 days ago · marketbeat.com
What Repligen (RGEN) Said on Its Q3 Earnings CallRepligen NASDAQ: RGEN reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises offset weakness in Filtration.
21 days ago · zacks.com
Repligen (RGEN) Q3 Earnings and Revenues Surpass EstimatesRepligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.46 per share a year ago.
21 days ago · globenewswire.com
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial GuidanceThird quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife acquisition, which fast-tracks Repligen's leadership and offering in high-growth cell therapy market Raising FY26 revenue guidance to $844-$852 million which represents reported revenue growth of 14.5% - 15.5% WALTHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today reported financial results for its third quarter of 2026, covering the three-month period ended September 30, 2026.
1 month ago · seekingalpha.com
Repligen: A Buy As Its Growth Engine Gears UpRepligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the Proteins and Process Analytics segments. Filtration's drag is temporary, with mid-single-digit growth expected in 2026 and order activity fueling a robust 2027 backlog. The BioLife acquisition adds high-margin, sticky cell therapy consumables, with anticipated synergies and accretive EPS contributions post-closing.
1 month ago · globenewswire.com
Repligen to Report Third Quarter 2026 Financial ResultsWALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that the Company will report its third quarter 2026 financial results on Tuesday, October 27, 2026.
1 month ago · gurufocus.com
Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tells InvestorsOn October 06, 2026, Repligen Corp (RGEN) shares experienced a notable decline of 7.7%, bringing the current price to $174.86. This movement comes amid a 52-wee
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RGEN